ANL

Adlai Nortye Ltd. operates as a biopharmaceutical company focused on developing and commercializing targeted cancer therapies in China and other Asian markets. Headquartered in Hong Kong, the company specializes in bringing proven oncology treatments to underserved patient populations through licensing agreements and strategic partnerships with global pharmaceutical companies. ANL's portfolio includes several oncology products at various stages of development and commercialization, with particular emphasis on treatments for lung cancer, lymphoma, and other hematologic malignancies. The company's business model centers on in-licensing late-stage or approved cancer drugs from international partners, conducting bridging studies for regulatory approval in Greater China, and establishing commercial infrastructure for distribution. ANL maintains research and development operations alongside its commercial activities, employing approximately 150 professionals across its Hong Kong headquarters and mainland China offices. The company secured regulatory approval for its lead product in 2019 and has since expanded its pipeline through multiple licensing agreements. ANL's market position reflects its focus on addressing the significant unmet medical needs in Chinese oncology markets, where access to innovative cancer treatments remains limited compared to Western markets. Recent developments include the advancement of several pipeline candidates through clinical trials and the expansion of its commercial footprint across key provincial markets in China.